Oppenheimer & CO Inc Biomea Fusion, Inc. Transaction History
Oppenheimer & CO Inc
- $5.91 Billion
- Q1 2024
A detailed history of Oppenheimer & CO Inc transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 13,704 shares of BMEA stock, worth $61,668. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,704
Previous 25,362
45.97%
Holding current value
$61,668
Previous $368,000
44.57%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BMEA
# of Institutions
121Shares Held
25.7MCall Options Held
2.56MPut Options Held
879K-
State Street Corp Boston, MA4.49MShares$20.2 Million0.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.57MShares$16.1 Million3.07% of portfolio
-
Laurion Capital Management LP New York, NY2.72MShares$12.2 Million0.36% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$9.49 Million0.4% of portfolio
-
Black Rock Inc. New York, NY1.97MShares$8.88 Million0.0% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $132M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...